Radio-Labeled Synthesis

Overview

Early stage knowledge of the pharmacological effects of an investigational drug in the human body has become increasingly important in order to avoid costly late-stage clinical trial failures. For this reason, industry is more frequently conducting ADME studies in humans to better evaluate the performance of a drug early in the development cycle (usually in Phase I).

In order to study a drug's disposition, it is common to place a radioactive tag at a metabolically stable site on the investigational drug. Using the radioactive tag, we are able to identify any metabolites and detect structurally unidentified metabolites. Performing radiolabeled synthesis at an early stage, allows drug developers to make informed decisions about committing resources to the development of a chemical entity for commercial application, thereby reducing financial risk.

Sekisui XenoTech's global research team has over 50 years of experience synthesizing radiolabeled compounds and offers the following radiolabeled synthesis services:
  • 14C and 3H-labeled compound synthesis
  • 14C-fermentation
  • 3H, 33S, 35S, 90Y, 125I and 111In protein and peptide labeling
  • Re-purification and stability test
  • Storage / re-analysis
  • Synthesis of biologically active substances
  Find the Services You Need  
How Can We Help You?
(please note: pressing Enter will submit the form)
Or Call 1-877-588-7530
(+1.913.438.7450 If Outside North America)


<< In vivo ADME
Pharmacokinetics
Whole-Body Autoradiography
Contact Us

Contact Us

Questions or inquiries? Use our contact form and we’ll reply as soon as possible.* indicates required field

Request A Quote
Request A Quote

Request A Quote

 Security code